Summary & Overview
HCPCS Level II C9089: Bupivacaine Collagen-Matrix Implant, 1 mg
HCPCS Level II code C9089 denotes a bupivacaine, collagen-matrix implant, 1 mg — a localized, extended-release anesthetic device used to provide prolonged postoperative analgesia at surgical sites. Nationally, the code matters for facility billing, device reimbursement policies, and integration into perioperative pain-management protocols because it represents a single-use implantable local anesthetic that may affect procedure-level costs and pain-control strategies.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The summary covers considerations relevant across commercial and federal payers for coverage determinations, coding consistency, and potential documentation expectations.
Readers will learn the clinical context of the product, typical sites of service where the implant is used, and the administrative implications of billing under C9089. The publication provides benchmarks and policy-oriented updates where available, clarifies service-line placement for procedural reporting, and outlines the operational details that matter to coding and billing teams. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C9089 represents Bupivacaine, collagen-matrix implant, 1 mg. This code describes a localized, sustained-release formulation of bupivacaine embedded in a collagen matrix intended to provide prolonged postoperative local anesthesia.
Service Type: Local anesthetic implant/device
Typical Site of Service: Hospital inpatient or outpatient surgical settings, ambulatory surgery centers, and other procedural sites where surgical wound analgesia is administered.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 45–70-year-old adult undergoing open or minimally invasive surgical resection of a soft-tissue lesion (for example, excision of a tumor or major musculoskeletal procedure) in which local postoperative analgesia is desired at the surgical site. During the procedure the surgeon identifies a wound bed where prolonged local anesthetic delivery is clinically appropriate to reduce postoperative pain and opioid need. A sterile bupivacaine collagen-matrix implant (listed as C9089, 1 mg) is placed directly into the wound bed or adjacent to peripheral nerve branches before layered closure. The implant provides sustained local anesthetic release over hours to days. Typical intraoperative workflow includes documentation of implant lot number and quantity in the operative report and implant log, adding the implant charge to the operative encounter, and coding the device with C9089 on the hospital outpatient or inpatient claim. Common sites of service are hospital outpatient surgical departments, inpatient operating rooms, ambulatory surgical centers, and occasionally office-based surgical suites when the facility bills for implants. Typical clinical team members include the operating surgeon (orthopedic, general, plastic, or neurosurgeon), circulating nurse, scrub tech, and anesthesia provider; documentation should support medical necessity for local analgesia adjunct and specify location and number of implants placed.
Coding Specifications
| Modifier | Description | When to Use |
|---|